Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes,... see more

TSX:LABS - Post Discussion

Medipharm Labs Corp > Global cannabis pharmaceutical outlook
View:
Comment by Solid1 on Dec 17, 2023 3:51pm
 Insys Therapeutics, Inc. is bankrupt... people pay money for that ?
Comment by Olaf123 on Dec 18, 2023 8:36am
Restrains: Thus, while quality control and standardization are essential for ensuring patient safety and product efficacy in the cannabis pharmaceuticals market, excessive regulatory burden and uniformity requirements may hamper market growth by increasing costs and limiting product diversity and innovation. They include a struggling company like Avicanna. They don't include Medipharm which ...more  
Comment by subaru1i on Dec 18, 2023 8:48am
Those reports can be very expensive and the only way those growth numbers gain credibility is if the projections are sourced from global pharmaceutical companies that intended to commercialize cannabis based pharmaceuticals.  And having written that within this forum, I can only say, we are in a very, very, sweet spot with LABS stock.   Nicely done alleyesonme and let the trend be ...more  
Comment by Olaf123 on Dec 18, 2023 8:57am
With Labs NDA, I'm not certain their research is very precise. October 2023. They had plenty of time.
Comment by subaru1i on Dec 18, 2023 9:15am
I think the FDA would disagree with your comment of their research not being precise because the NIH is using product from LABS for clinical trials and the FDA also approved their facility.   I disagree with your comments w.r.t. NDA submission because that submission was executed in conjunction with their yet to be named global pharmaceutical partner and proof of that is that no record ...more  
Comment by Olaf123 on Dec 18, 2023 9:24am
Apotex ain't mentioned here either.
Comment by mdjbrown on Dec 18, 2023 11:29am
Speaking of Apotex -  New Jersey lawsuit 2:23-cv23141 with Jazz / GW regarding Epidiolex moving right along https://www.pacermonitor.com/public/case/51713587/JAZZ_PHARMACEUTICALS_RESEARCH_UK_LIMITED_fka_GW_RESEARCH_LIMITED_v_APOTEX_INC_et_al 2:23-cv-23141
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities